Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery

NCT02493179 is registered in ClinicalTrials.gov with Hayat Pharmaceutical Co. PLC as lead sponsor.

NCT NCT02493179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery
Lead sponsor
Hayat Pharmaceutical Co. PLC
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2015
Completion date
February 29, 2016
Enrollment
112 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

inflammation, swelling, trismus